Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism

Jean‐Charles Lambert(Inserm), Florie Demiautte(Inserm), Fanny Eysert(Centre National de la Recherche Scientifique), Elaine R. Peskind(Inserm), John Q. Trojanowski(University of Pennsylvania), Kaj Blennow(Sahlgrenska University Hospital), Adrien Herlédan(Inserm), Charlotte Bauer(Centre National de la Recherche Scientifique), Philippe Amouyel(Inserm), Virginie Pottiez(Centre National de la Recherche Scientifique), Carlos Cruchaga(Washington University in St. Louis), Vivianna M. Van Deerlin(Hospital of the University of Pennsylvania), Ronald C. Petersen(Mayo Clinic in Arizona), Amandine Flaig(Inserm), Florence Leroux(Inserm), Gaspard Deloison(Centre National de la Recherche Scientifique), Pierre Dourlen(Inserm), Virginia Man-Yee Lee(University of Pennsylvania), Abhay Moghekar(Johns Hopkins University), Julien Chapuis(Inserm), Richard M. O’Brien(Vanderbilt University), Priscille Brodin(Centre National de la Recherche Scientifique), Henrik Zetterberg(University of Wisconsin–Madison), Ok‐Ryul Song(Centre National de la Recherche Scientifique), Lennart Minthon(Lund University), Tiago Mendes(Universidade Federal de Viçosa), Benoît Déprez(Centre National de la Recherche Scientifique), Frédéric Checler(Centre National de la Recherche Scientifique), Shruti Desai(Inserm), Alexandre Vandeputte(Centre National de la Recherche Scientifique), Alison Goate(Washington University in St. Louis), Leslie M. Shaw(California University of Pennsylvania), Gerard D. Schellenberg(University of Pennsylvania), John Kauwe(Brigham Young University), Nicolas Malmanche(Universidade do Porto), Benjamin Grenier‐Boley(University of Bonn), Anne‐Marie Ayral(Inserm), Marilyn Albert(Johns Hopkins Medicine)
Acta Neuropathologica
December 8, 2016
Cited by 78


Related Papers